Please login to the form below

Not currently logged in
Email:
Password:

drug abuse

This page shows the latest drug abuse news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs J&J’s new-class antidepressant

FDA panel backs J&J’s new-class antidepressant

have potential for abuse, like its parent drug ketamine. ... It has listed the drug as a potential $1bn product, although Evaluate analysts are a bit more conservative, predicting annual revenues of $490m by 2020.

Latest news

  • AcelRX’s potent opioid tablets set to win FDA backing for pain relief AcelRX’s potent opioid tablets set to win FDA backing for pain relief

    This time the application included a Risk Evaluation Mitigation Strategy (REMS), stating that the drug must be administered by a trained healthcare professional to avoid substance abuse and accidental exposures. ... This measure has helped to swing the

  • FDA panel backs Indivior’s drug to fight opioid addiction FDA panel backs Indivior’s drug to fight opioid addiction

    Indivior is on course to bring a new drug to market to tackle painkiller addiction in the US, offsetting the risks to its business from generic competition. ... An FDA advisory committee backed approval of Indivior’s RBP-6000 drug by a vote of eighteen

  • FDA panel backs Pfizer and Teva abuse-resistant painkillers FDA panel backs Pfizer and Teva abuse-resistant painkillers

    However, it would not back a label claim that the product could prevent abuse of the drug via the oral route, but said it could discourage abuse by people seeking to ... Last month the same panel also rejected an abuse-deterrent claim for KemPharm's

  • FDA gives green light for opioid addiction implant FDA gives green light for opioid addiction implant

    He added: “Opioid abuse and addiction have taken a devastating toll on American families. ... Nora Volkow, director of the National Institute on Drug Abuse, said: “Scientific evidence suggests that maintenance treatment with these medications in the

  • FDA panel backs Novo Nordisk's liraglutide for obesity FDA panel backs Novo Nordisk's liraglutide for obesity

    Committee says diabetes drug could be used to reduce weight.  . Novo Nordisk's liraglutide should be approved to help reduce weight in obese people with at least one accompanying health issue ... Orexigen said yesterday that Contrave will have the

More from news
Approximately 3 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Pharma deals during January 2013 Pharma deals during January 2013

    9.5. Savant HWP / National Institute on Drug Abuse. Development grant. ... 18-MC (18-methoxycoronaridine) as a treatment for drug addiction, obesity and compulsive behaviour.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • "Legal highs" ruling leaves illegal labs laughing

    We have also pitched for agents designed to treat opioid overdose and alcohol abuse.  . ... Drug abuse is a massive medical and social problem in the UK, and it has been compounded by the availability of new psychoactive agents virtually everywhere.

  • How digital content is helping physicians curb the opioid abuse epidemic

    using their state’s Prescription Drug Monitoring Program (PDMP) database before prescribing opioids to a patient. ... After all, having physicians more frequently access these state PMDPs at the point of prescription can go a long way to preventing

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics